论文部分内容阅读
Astrocytes in an in vitro murine astrocyte model of oxygen and glucose deprivation/hypoxia and reoxygenation were treated with different concentrations of triptolide (250, 500, 1 000 ng/mL) in a broader attempt to elucidate the protection and mechanism underlying triptolide treatment on astrocytes exposed to hypoxia/reoxygenation injury. The results showed that the matrix metalloproteinase-9, interleukin-1β, tumor necrosis factor α and interleukin-6 expressions were significantly decreased after triptolide treatment in the astrocytes exposed to hypoxia/ reoxygenation injury, while interleukin-10 expression was upregulated. In addition, the vitality of the injured astrocytes was enhanced, the triptolide’s effect was apparent at 500 ng/mL. These experimental findings indicate that triptolide treatment could protect astrocytes against hypoxia/ reoxygenation injury through the inhibition of inflammatory response and the reduction of matrix metalloproteinase-9 expression.
Astrocytes in an in vitro murine astrocyte model of oxygen and glucose deprivation / hypoxia and reoxygenation were treated with different concentrations of triptolide (250, 500, 1000 ng / mL) in a broader attempt to elucidate the protection and mechanism of the underlying triptolide treatment on astrocytes The results showed that the matrix metalloproteinase-9, interleukin-1β, tumor necrosis factor α and interleukin-6 expressions were significantly decreased after triptolide treatment in the astrocytes exposed to hypoxia / reoxygenation injury, while interleukin-10 expression was upregulated. In addition, the vitality of the injured astrocytes was enhanced, the triptolide’s effect was apparent at 500 ng / mL. These experimental findings indicate that triptolide treatment could protect astrocytes against hypoxia / reoxygenation injury through the inhibition of inflammatory response and the reduction of matrix metalloproteinase-9 expression.